Alvotech (ALVO) Non-Current Deferred Tax Liability (2020 - 2026)
Alvotech's (ALVO) quarterly Non-Current Deferred Tax Liability came in at $7.2 million in Q1 2026, up 248.1% YoY from $2.1 million in Q1 2025, and down 8.95% on a QoQ basis from $7.9 million in Q4 2025.
Alvotech (ALVO) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 248.1% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 248.1% YoY) and the FY2025 annual result came in at $7.9 million, up 334.46% from the prior year.
- Non-Current Deferred Tax Liability retreated to $7.2 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.9 million in Q4 2025 to a low of $45000.0 in Q2 2023.
- A 5-year average of $2.4 million and a median of $1.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability plunged 82.85% — and 2024, when it soared 3316.98%.
- Tracing ALVO's Non-Current Deferred Tax Liability over 5 years: stood at $309000.0 in 2022, then sank by 82.85% to $53000.0 in 2023, then soared by 3316.98% to $1.8 million in 2024, then soared by 334.46% to $7.9 million in 2025, then decreased by 8.95% to $7.2 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $7.2 million (Q1 2026), $7.9 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.16 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 53,000.00 |
| Dec 31, 2023 | 53,000.00 |